"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESThe Inflation Reduction Act’s Medicare Drug Price Negotiation Program represents a paradigm shift in drug pricing policy in the U.S.
For drugs selected for maximum fair price (MFP) setting, the window for achieving returns is likely to condense as the MFP setting comes into effect at 9 years post-initial FDA approval for small molecules and 13 years for biologics. This changing dynamic suggests that clinical development post-initial approval may be adversely impacted.
Understanding the historical trends in this development is crucial for assessing the potential effects of this policy on innovation and implications for stakeholders.
The IQVIA Institute for Human Data Science is convening a multidisciplinary webinar to discuss the drug lifecycle, post-approval expansions, and the impacts of the IRA’s Price Negotiations Program on the future of innovation.
Caleb Alexander, MD, MS
Professor of Epidemiology and Medicine, Johns Hopkins University
John O’Brien, PharmD, MPH
President and CEO, National Pharmaceutical Council
Sean Nicholson, Ph.D.
Professor of Policy Analysis and Management, Cornell University
Robert Popovian, Pharm.D., M.S.
Chief Science Policy Officer, Global Healthy Living Foundation
Understand how payers, providers, and patients define value, and accelerate market access for new and innovative products.
